Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines

European Respiratory Review

Volumn 23, Issue 132, 2014, Pages 193-214

  Cottin, Vincent ^a   Crestani, Bruno ^b   Valeyre, Dominique ^c   Wallaert, Benoit ^d   Cadranel, Jacques ^e   Dalphin, Jean Charles ^f   Delaval, Philippe ^g   Israel Biet, Dominique ^h   Kessler, Romain ⁱ   Reynaud Gaubert, Martine ^j   Aguilaniu, Bernard ^k   Bouquillon, Benoit ^l   Carré, Philippe ^m   Danel, Claire ^b   Faivre, Jean Baptiste ^d   Ferretti, Gilbert ⁿ   Just, Nicolas ^o   Kouzan, Serge ^p   Lebargy, François ^q   Marchand Adam, Sylvain ^r   Philippe, Bruno ^s   Prévot, Grégoire ^t   Stach, Bruno ^u   Thivolet Béjui, Françoise ^v   Cordier, Jean François ^v   more..

^a University Lyon i   (France)

^b BICHAT HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^k Clinique du Mail   (France)

^l Opened Mind Health   (France)

^m Polyclinique Montréal ^*  (France)

ⁿ HÔPITAL MICHALLON   (France)

^o CENTRE HOSPITALIER DE ROUBAIX   (France)

^p Centre Hospitalier Intercommunal Sud Léman   (France)

^q HÔPITAL MAISON BLANCHE   (France)

^r UNIVERSITY HOSPITAL OF TOURS   (France)

^s CENTRE HOSPITALIER RENÉ DUBOS   (France)

^t SERVICE DE PNEUMOLOGIE   (France)

^u Cabinet medical   (France)

^v LOUIS PRADEL HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTIVITAMIN K; AZATHIOPRINE; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GAMMA1B INTERFERON; MACITENTAN; OXYGEN; PIRFENIDONE; PLACEBO; PREDNISONE; WARFARIN;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; COMPETENCE; COMPUTER ASSISTED TOMOGRAPHY; COORDINATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSKERATOSIS; EMPHYSEMA; EXERCISE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FRANCE; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LANGERHANS CELL HISTIOCYTOSIS; LEUKOPLAKIA; LOEFFLER PNEUMONIA; LOW DRUG DOSE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MEDICAL PRACTICE; MEGALOCYTOSIS; MONOTHERAPY; OXYGEN THERAPY; POLYSOMNOGRAPHY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; PULMONOLOGIST; QUALITY OF LIFE; REHABILITATION; REVIEW; SLEEP DISORDERED BREATHING; SMOKING CESSATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; CONSENSUS; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; IDIOPATHIC PULMONARY FIBROSIS; PREDICTIVE VALUE; PULMONOLOGY; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

CONSENSUS; DIAGNOSTIC IMAGING; EVIDENCE-BASED MEDICINE; FRANCE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PREDICTIVE VALUE OF TESTS; PULMONARY MEDICINE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84901754507     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001814     Document Type: Review

References (122)

1. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355-361.
2. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Wuyts WA, Peccatori FA, Russell A-M. Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models. Eur Respir Rev 2014; 23: 231-238.
4. Cottin V, Crestani B, Valeyre D, et al. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Elaborées par le Centre national de référence et les Centres de compétence pour les maladies pulmonaires rares sous l'égide de la Société de pneumologie de langue française [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française]. Rev Mal Respir 2013; 30: 879-902.
5. Haute Autorité de Santé. Élaboration de recommandations de bonne pratique. Méthode. Recommandations pour la pratique clinique. HAS, 2010.
6. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985.
7. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. Br Med J 1990; 301: 1015-1017.
8. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996; 153: 1548-1552.
9. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-142.
10. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161: 1172-1178.
11. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
12. Cottin V, Cordier JF. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012; 40: 519-521.
13. Bohadana A, Izbicki G, Kraman SS. Fundamentals of lung auscultation. N Engl J Med 2014; 370: 744-751.
14. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
15. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
16. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28: 893-896.
17. Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008; 102: 1392-1398.
18. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185: 1004-1014.
19. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043-1047.
20. Bitterman PB, Rennard SI, Keogh BA, et al. Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. N Engl J Med 1986; 314: 1343-1347.
21. Marshall RP, Puddicombe A, Cookson WO, et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55: 143-146.
22. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342.
23. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127: 2034-2041.
24. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146-1152.
25. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698-705.
26. Musk AW, Zilko PJ, Manners P, et al. Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm). Chest 1986; 89: 206-210.
27. Young NS. Telomere biology and telomere diseases: implications for practice and research. Hematology Am Soc Hematol Educ Program 2010; 2010: 30-35.
28. Cottin V, Capron F, Grenier P, et al. Pneumopathies interstitielles diffuses idiopathiques. Classification de Consensus International Multidisciplinaire de l'American Thoracic Society et de l'European Respiratory Society, principales entités anatomo-cliniques, et conduite du diagnostic [Diffuse idiopathic interstitial pneumonias. International multidisciplinary consensus classification by the American Thoracic Society and the European Respiratory Society, principal clinico-pathological entities, and diagnosis]. Rev Mal Respir 2004; 21: 299-318.
29. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
30. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
31. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
32. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathicpulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
33. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
34. Demedts M, Behr J, Buhl R, et al. IFIGENIA: effects of N-acetylcysteine (NAC) on primary end points VC and DL,CO. Eur Respir J 2004; 24: Suppl. 48s, 668s.
35. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
36. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 209-214.
37. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063-1072.
38. Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978; 65: 661-672.
39. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
40. Johnson MA, Kwan S, Snell NJ, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
41. Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125: 2169-2174.
42. Pereira CA, Malheiros T, Coletta EM, et al. Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids. Respir Med 2006; 100: 340-347.
43. Hope-Gill BD, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 995-1002.
44. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
45. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
46. Fiorucci E, Lucantoni G, Paone G, et al. Colchicine, cyclophosphamide and prednisone in the treatment of mildmoderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008; 12: 105-111.
47. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006; 28: 496-504.
48. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158: 220-225.
49. Grgic A, Lausberg H, Heinrich M, et al. Progression of fibrosis in usual interstitial pneumonia: serial evaluation of the native lung after single lung transplantation. Respiration 2008; 76: 139-145.
50. Wahidi MM, Ravenel J, Palmer SM, et al. Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation. Chest 2002; 121: 2072-2076.
51. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon-c-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
52. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon-c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
53. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
54. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
55. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
56. Raghu G, Million-Rousseau R, Morganti A, et al. Efficacy and safety of macitentan in idiopathic pulmonary fibrosis: results of a prospective, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2012; 185: A3631.
57. Raghu G, Behr J, Brown KK, et al. ARTEMIS-IPF: a placebo-controlled trial of ambrisentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: A3632.
58. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
59. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
60. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-398.
61. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.
62. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-554.
63. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394-399.
64. Mason DP, Brizzio ME, Alster JM, et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007; 84: 1121-1128.
65. Keating D, Levvey B, Kotsimbos T, et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc 2009; 41: 289-291.
66. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469-475.
67. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
68. Raghu G. Idiopathic pulmonary fibrosis: increased survival with "gastroesophageal reflux therapy": fact or fallacy? Am J Respir Crit Care Med 2011; 184: 1330-1332.
69. Morawiec E, Tillie-Leblond I, Pansini V, et al. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J 2011; 38: 1487-1489.
70. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001; 120: 209-212.
71. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143-150.
72. Molina-Molina M, Badia JR, Marin-Arguedas A, et al. Características clínicas y pronóstico de los pacientes con fibrosis pulmonar que ingresan en cuidados intensivos por insuficiencia respiratoria. Análisis de 20 casos [Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit. A study of 20 cases]. Med Clin (Barc) 2003; 121: 63-67.
73. Saydain G, Islam A, Afessa B, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002; 166: 839-842.
74. Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax 1999; 54: 390-395.
75. Stern JB, Mal H, Groussard O, et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest 2001; 120: 213-219.
76. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11: 117-122.
77. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med 2001; 27: 1868-1874.
78. Mollica C, Paone G, Conti V, et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration 2010; 79: 209-215.
79. Rangappa P, Moran JL. Outcomes of patients admitted to the intensive care unit with idiopathic pulmonary fibrosis. Crit Care Resusc 2009; 11: 102-109.
80. Mullier A, Cottin V, Richard J-C, et al. Fibrose pulmonaire: dans quels cas et sur quels critères envisager une admission en réanimation? [Pulmonary fibrosis: which patient should be admitted to the ICU and based on which critera?]. Réanimation 2013; 22: 45-53.
81. Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010; 49: 1509-1514.
82. Nathan SD, Cottin V. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. In: Hoeper MH, Humbert M, eds. Pulmonary Hypertension. ERS Monogr 2012; 57: 148-160.
83. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: Suppl. 25, D109-D116.
84. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721.
85. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
86. Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: 93-100.
87. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740.
88. Madden BP, Allenby M, Loke TK, et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006; 44: 372-376.
89. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-899.
90. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
91. Han MK, Bach DS, Hagan P, et al. Sildenafil preserves exercise capacity in IPF patients with right ventricular dysfunction. Chest 2013; 143: 1699-1708.
92. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013; 41: 853-860.
93. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 344-351.
94. Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Care Med 1998; 158: 1804-1808.
95. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133: 1078-1084.
96. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011; 66: 226-231.
97. Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131: 438-446.
98. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390-1394.
99. Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for antireflux therapy? Eur Respir J 2012; 39: 242-245.
100. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct under recognized entity. Eur Respir J 2005; 26: 586-593.
101. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
102. Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
103. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011; 38: 176-183.
104. Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 1209-1215.
105. Clark M, Cooper B, Singh S, et al. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001; 56: 482-486.
106. Aydogdu M, Ciftci B, Firat Guven S, et al. Interstisyel akciger hastalarinda polisomnografi ile uyku ozelliklerinin degerlendirilmesi [Assessment of sleep with polysomnography in patients with interstitial lung disease]. Tuberk Toraks 2006; 54: 213-221.
107. Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung 2007; 185: 173-178.
108. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136: 772-778.
109. Recommandations pour la Pratique Clinique Syndrome d'apnées hyperpnées obstructives du sommeil de l'adulte [Recommendations for clinical practice. Obstructive sleep apnea hypopnea syndrome in adults]. Rev Mal Respir 2010; 27: 806-833.
110. Allen S, Raut S, Woollard J, et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med 2005; 19: 128-130.
111. Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
112. Morrison DA, Stovall JR. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest 1992; 102: 542-550.
113. Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011; 38: 987-990.
114. Frank RC, Hicks S, Duck AM, et al. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J 2012; 40: 269-270.
115. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
116. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8.
117. Turner-Warwick ME, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.
118. Harris JM, Johnston ID, Rudd R, et al. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010; 65: 70-76.
119. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14: 723-728.
120. Fell CD. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. Clin Chest Med 2012; 33: 51-57.
121. Behr J. Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 163-168.
122. Xaubet A, Behr J, Bendstrup E, et al. Review of IPF diagnosis and management recommendations in Europe. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 249-261.